Nav: Home

New study mapping pandemic potential could help prevent future disease outbreaks

October 11, 2017

SEATTLE - A new scientific study provides the first evidence-based assessment of pandemic potential in Africa prior to outbreaks and identifies ways to prevent them.

The study, published today in the international medical journal The Lancet, examines the potential for the widespread onset of Ebola or other lethal viral hemorrhagic fevers emanating from communities in African countries. A team of international researchers examined the relative likelihood of four deadly viruses emerging and spreading at several key stages in a possible pandemic, charting and quantifying progress from the first human case through to a widespread epidemic.

Data visualizations from the paper are available at https://vizhub.healthdata.

By mapping the greatest vulnerabilities for initial cases to escalate into epidemics, more precise preparedness activities can be implemented.

A data visualization

"In the absence of strong surveillance and response systems, infectious disease outbreaks can quickly overwhelm a country's health system," said Dr. Simon I. Hay, Director of Geospatial Science at the Institute for Health Metrics and Evaluation (IHME), an independent global health research organization at the University of Washington in Seattle. "As we have seen with Ebola, it is absolutely vital to prevent or stop epidemics at the earliest possible stages. With a focus on Africa, this study's framework provides an important tool for pinpointing where local surveillance and pre-emptive countermeasures are most needed."

esearchers focused on four diseases - Ebola virus disease, Marburg virus disease, Lassa fever, and Crimean-Congo hemorrhagic fever - since the way they move from animal sources to humans is similar. The study's results showed considerable differences in the potential for these pathogens to spread both between countries as well as within and among communities in an individual country. For example, researchers identified stark contrasts in the vulnerability between Nigeria's northern and southern states.

"Understanding subnational variation in pandemic potential is a crucial part of preventing and responding to disease outbreaks," said Dr. David Pigott, lead author of the study. "These results show that national assessments can mask significant subnational differences - which could be the difference between quick case detection and treatment, or early cases going unchecked and resulting in a large-scale epidemic. National assessments are an important first step, but are insufficient on their own to strengthen local disease surveillance, response, and preparedness needs."

While the study identifies at-risk locations that have witnessed outbreaks, it also highlights large areas of the continent currently considered not at risk, much like Guinea prior to 2013, when the transmission of the Ebola virus led to more than 25,000 reported cases and 10,000 deaths in three countries, according to the World Health Organization.

Parts of Central African Republic, Chad, Somalia, and South Sudan rank as highly vulnerable to any outbreak. Areas around the Congo River in Central Africa rank highest for local outbreak potential for Ebola and Marburg virus disease. In contrast, parts of West Africa rank highest as sources of widespread epidemics for all four viruses. For example, Guéckédou prefecture in Guinea, where the 2013-2016 Ebola outbreak originated, ranks as one of the most likely districts for an individual Ebola case to result in a widespread epidemic.

Dr. Peter Piot, Director of the London School of Hygiene & Tropical Medicine and a co-author of the study, noted, "By assessing pandemic potential at these different stages, we can begin to identify locations where different interventions or prevention measures could have the greatest impact. The various stages reflect important transitions in an outbreak and influence what interventions should be prioritized in which location."

Such efforts can range from focusing on surveillance of animals involved in transmission, rapid detection of the first case of an outbreak, or providing resources for improving health systems prior to the next outbreak. Similarly, after an outbreak has started, assessments could guide future vaccination efforts to contain any local outbreak and stop further spread.

"Pairing these assessments of epidemic potential with in-country knowledge of existing local preparedness initiatives and preventive programs is a crucial next step," said Dr. Osman Sankoh, a study co-author and Executive Director of INDEPTH Network, a Ghana-based international network of representatives from health and demographic surveillance systems in low- and middle-income countries. "With estimates like these we can begin to work with local decision-makers to evaluate their existing strategies and plan for the future, a future where these diseases and their deadly consequences can be prevented."

IHME researchers and collaborators contributing to the study anticipate refining and expanding the framework in the future, according to Dr. Pigott.

"The intention was to create an approach that allows for other diseases, or other regions of the world, to be considered," he said. "We hope to expand and improve upon this initial assessment to make sure that we consider all paths to a potential pandemic."

The study is entitled "Local, national, and regional viral haemorrhagic fever pandemic potential in Africa: a multistage analysis." Results accompanying the study are available in an interactive web tool.
Media contacts:

Kelly Bienhoff
1-206-897-2884 (office)
1-913-302-3817 (cell)

Dean R. Owen
1 -206-897-2858 (office)
1-206-434-5630 (cell)

For interviews with Professor Peter Piot, please email or phone 44-0-207-927-2802, or contact either Ms. Bienhoff or Mr. Owen.

Established in 2007, the Institute for Health Metrics and Evaluation (IHME) is an independent global health research center at the University of Washington in Seattle that provides rigorous and comparable measurement of the world's most important health problems and evaluates strategies to address them. IHME makes this information available so that policymakers, donors, practitioners, researchers, and local and global decision-makers have the evidence they need to make informed decisions about how to allocate resources for improving population health. For more information, visit

Institute for Health Metrics and Evaluation

Related Ebola Articles:

Ebola antibodies at work
Scientists in Israel and Germany show, on the molecular level, how an experimental vaccine offers long-term protection against the disease.
Half of Ebola outbreaks undetected
An estimated half of Ebola virus disease outbreaks have gone undetected since it was discovered in 1976, according to research published in PLOS Neglected Tropical Diseases.
Half of Ebola outbreaks go undetected, study finds
Half of Ebola outbreaks have gone undetected since the virus was discovered in 1976, scientists at the University of Cambridge estimate.
Protecting those on the frontline from Ebola
Online training developed at the Medical University of South Carolina (MUSC) increased the knowledge of health care workers about effective prevention of Ebola up to 19 percent and reduced critical errors to 2.3 percent in a small MUSC cohort.
Another piece of Ebola virus puzzle identified
A team of researchers have discovered the interaction between an Ebola virus protein and a protein in human cells that may be an important key to unlocking the pathway of replication of the killer disease in human hosts.
How the human immune system protects against Ebola
'The current approach for treatment of filovirus infections with antibody cocktails tested in animal models utilizes the principle of targeting of non-overlapping epitopes.
How to slow down Ebola
The phylogenetic tree of the 2013-2016 Ebola epidemic doesn't just tell us how the Ebola virus was able to evolve: it also reveals which events and preventive measures accelerated or slowed down its spread.
Study provides further insight into how Ebola affects the eye
A new study, conducted by the researchers from the University of Liverpool, published in JAMA Ophthalmology identifies the specific characteristics of Ebola retinal lesions, which provide further clues as to how the virus travels to the retina and causes damage.
New breakthrough paving the way for universal Ebola therapeutic
A new collaborative study has identified and studied Ebola antibodies that could be used to design universal therapeutics that are effective against many different Ebola species.
Preprints accelerated between Ebola and Zika epidemics
Preprints -- scientific manuscripts that are posted at a recognized online repository before peer review -- have the potential to speed up the reporting of scientific research in infectious disease outbreaks, argue Michael Johansson and colleagues in an Essay in PLOS Medicine.
More Ebola News and Ebola Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Teaching For Better Humans 2.0
More than test scores or good grades–what do kids need for the future? This hour, TED speakers explore how to help children grow into better humans, both during and after this time of crisis. Guests include educators Richard Culatta and Liz Kleinrock, psychologist Thomas Curran, and writer Jacqueline Woodson.
Now Playing: Science for the People

#556 The Power of Friendship
It's 2020 and times are tough. Maybe some of us are learning about social distancing the hard way. Maybe we just are all a little anxious. No matter what, we could probably use a friend. But what is a friend, exactly? And why do we need them so much? This week host Bethany Brookshire speaks with Lydia Denworth, author of the new book "Friendship: The Evolution, Biology, and Extraordinary Power of Life's Fundamental Bond". This episode is hosted by Bethany Brookshire, science writer from Science News.
Now Playing: Radiolab

Dispatch 3: Shared Immunity
More than a million people have caught Covid-19, and tens of thousands have died. But thousands more have survived and recovered. A week or so ago (aka, what feels like ten years in corona time) producer Molly Webster learned that many of those survivors possess a kind of superpower: antibodies trained to fight the virus. Not only that, they might be able to pass this power on to the people who are sick with corona, and still in the fight. Today we have the story of an experimental treatment that's popping up all over the country: convalescent plasma transfusion, a century-old procedure that some say may become one of our best weapons against this devastating, new disease.   If you have recovered from Covid-19 and want to donate plasma, national and local donation registries are gearing up to collect blood.  To sign up with the American Red Cross, a national organization that works in local communities, head here.  To find out more about the The National COVID-19 Convalescent Plasma Project, which we spoke about in our episode, including information on clinical trials or plasma donation projects in your community, go here.  And if you are in the greater New York City area, and want to donate convalescent plasma, head over to the New York Blood Center to sign up. Or, register with specific NYC hospitals here.   If you are sick with Covid-19, and are interested in participating in a clinical trial, or are looking for a plasma donor match, check in with your local hospital, university, or blood center for more; you can also find more information on trials at The National COVID-19 Convalescent Plasma Project. And lastly, Tatiana Prowell's tweet that tipped us off is here. This episode was reported by Molly Webster and produced by Pat Walters. Special thanks to Drs. Evan Bloch and Tim Byun, as well as the Albert Einstein College of Medicine.  Support Radiolab today at